{
    "nctId": "NCT00870168",
    "briefTitle": "Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer",
    "officialTitle": "Modifications of Hormone Receptors and Biological Parameters of Metastatic Breast Cancer Treated With First-line Chemotherapy. Prospective Biological Study.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Changes in hormone receptor expression",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Metastatic disease\n* No inflammatory breast cancer\n* Measurable disease according to RECIST criteria\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-negative by IHC\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* WHO performance status 0-2\n* Life expectancy \\> 3 months\n* ANC \\> 1.5 x 10\\^9/L\n* Platelet count \\> 100 x 10\\^9/L\n* Liver transaminases \u2264 3 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 3 times ULN\n* Bilirubin \u2264 1.5 times ULN\n* Creatinine \u2264 2 times ULN\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No allergy to xylocaine\n* No heart failure, or kidney, bone marrow, respiratory, or liver insufficiency\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior first-line treatment for metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}